{"name":"Asahi Kasei Pharma","slug":"asahi-kasei-pharma","ticker":"3407.T","exchange":"TSE","domain":"asahi-kasei.com","description":"Asahi Kasei Corporation engages in material, homes, healthcare businesses. The company offers Pimel photosensitive polyimide/PBO precursor, a liquid photosensitive material for buffer coating and packaging applications; Sunfort dry film photoresist to form circuit patterns on printed wiring boards; Novacure, a latent curing agent for epoxy resin with storage stability; glass fabric for printed circuit boards; plastic optical fiber; suede products under the Dinamica name; Microza UF and MF industrial membranes and systems; Aciplex membranes, process equipment, and systems for caustic soda production; Hipore, a microporous polyolefin sheet which prevents the anode and cathode from contacting one another; Celgard, a lithium-ion battery separator; Deramic, a lead acid battery separator; photopolymers and platemaking systems; and fiber products under the Bemberg, ROICA, ELTAS, Bemliese, EUTEC, Precisé, SEMIA, smash, PULSHUT, Lastan, Cubit, NanoAct, ECORISE, BioCradle, CMC-Bemliese names. It","hq":"Tokyo, Japan","founded":0,"employees":"","ceo":"","sector":"Diversified / Pharma","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":1729,"stockChange":-21,"stockChangePercent":-1.2,"marketCap":"$14.8B","metrics":{"revenue":19436626454.86294,"revenueGrowth":2.1,"grossMargin":32.8,"rdSpend":0,"netIncome":1003869017.7686766,"cash":2383491063.4848847,"dividendYield":2.51,"peRatio":14.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"AK106-001616","genericName":"AK106-001616","slug":"ak106-001616","indication":"Other","status":"phase_2"},{"name":"AK159","genericName":"AK159","slug":"ak159","indication":"Other","status":"phase_1"},{"name":"AK1820","genericName":"AK1820","slug":"ak1820","indication":"Other","status":"phase_3"},{"name":"ART-123","genericName":"ART-123","slug":"art-123","indication":"Other","status":"marketed"},{"name":"HC-58","genericName":"HC-58","slug":"hc-58","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Cyclophosphamide (CTX)","genericName":"Cyclophosphamide (CTX)","slug":"cyclophosphamide-ctx","indication":"Lymphomas (Hodgkin and non-Hodgkin)","status":"phase_3"},{"name":"AK156","genericName":"AK156","slug":"ak156","indication":"Non-small cell lung cancer","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Mizoribine (MZR)","genericName":"Mizoribine (MZR)","slug":"mizoribine-mzr","indication":"Prevention of organ transplant rejection","status":"phase_3"}]}],"pipeline":[{"name":"Cyclophosphamide (CTX)","genericName":"Cyclophosphamide (CTX)","slug":"cyclophosphamide-ctx","phase":"phase_3","mechanism":"Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and triggering apoptosis in rapidly dividing cells.","indications":["Lymphomas (Hodgkin and non-Hodgkin)","Breast cancer","Ovarian cancer","Lung cancer","Severe systemic lupus erythematosus (SLE)"],"catalyst":""},{"name":"AK106-001616","genericName":"AK106-001616","slug":"ak106-001616","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK156","genericName":"AK156","slug":"ak156","phase":"phase_3","mechanism":"AK156 is a humanized monoclonal antibody that blocks the PD-1 checkpoint pathway to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"AK159","genericName":"AK159","slug":"ak159","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK1820","genericName":"AK1820","slug":"ak1820","phase":"phase_3","mechanism":"AK1820 is an investigational therapeutic targeting immune or inflammatory pathways, though its precise mechanism remains proprietary.","indications":[],"catalyst":""},{"name":"ART-123","genericName":"ART-123","slug":"art-123","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HC-58","genericName":"HC-58","slug":"hc-58","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mizoribine (MZR)","genericName":"Mizoribine (MZR)","slug":"mizoribine-mzr","phase":"phase_3","mechanism":"Mizoribine inhibits inosine monophosphate dehydrogenase (IMPDH) to suppress guanine nucleotide synthesis and reduce T and B cell proliferation.","indications":["Prevention of organ transplant rejection","Autoimmune and inflammatory diseases"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":8,"phaseCounts":{"phase_3":4,"phase_2":2,"phase_1":1,"marketed":1},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":19201496776.8704,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":19201496776.8704},{"period":"2024-03-31","value":17605641416.1526},{"period":"2023-03-31","value":17236488361.974503},{"period":"2022-03-31","value":15560130287.0289}],"grossProfit":6057996775.242001,"grossProfitHistory":[{"period":"2025-03-31","value":6057996775.242001},{"period":"2024-03-31","value":5158451329.1773},{"period":"2023-03-31","value":4891712596.539201},{"period":"2022-03-31","value":4866380856.6373005}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":1339731050.664,"operatingIncomeHistory":[{"period":"2025-03-31","value":1339731050.664},{"period":"2024-03-31","value":889778154.2882},{"period":"2023-03-31","value":807404166.0372001},{"period":"2022-03-31","value":1281108334.3899}],"netIncome":853433713.8849001,"netIncomeHistory":[{"period":"2025-03-31","value":853433713.8849001},{"period":"2024-03-31","value":276935911.69020003},{"period":"2023-03-31","value":-581277137.1999},{"period":"2022-03-31","value":1023384590.7960001}],"eps":99.403655,"epsHistory":[{"period":"2025-03-31","value":99.403655},{"period":"2024-03-31","value":31.6},{"period":"2023-03-31","value":-66.3},{"period":"2022-03-31","value":116.68}],"cash":2487447892.1839004,"cashHistory":[{"period":"2025-03-31","value":2487447892.1839004},{"period":"2024-03-31","value":2137475396.7436001},{"period":"2023-03-31","value":1587934055.4777},{"period":"2022-03-31","value":1546589014.5597}],"totalAssets":25383667756.0438,"totalLiabilities":13283959347.059,"totalDebt":7554921165.7265005,"equity":11755020998.2857,"operatingCashflow":1905974776.9613001,"operatingCashflowHistory":[{"period":"2025-03-31","value":1905974776.9613001},{"period":"2024-03-31","value":1866848713.0100002},{"period":"2023-03-31","value":574051237.8468001},{"period":"2022-03-31","value":1158615748.3307002}],"capex":-1377782396.4263,"capexHistory":[{"period":"2025-03-31","value":-1377782396.4263},{"period":"2024-03-31","value":-1087071126.3018},{"period":"2023-03-31","value":-1088360788.1286001},{"period":"2022-03-31","value":-1072872202.4636}],"freeCashflow":528192380.535,"dividendsPaid":-315853353.8754,"buybacks":-189776266.56230003,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2025-06-30","revenue":null,"epsBasic":14.517686,"netIncome":null,"rdExpense":null,"epsDiluted":14.517686,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1729,"previousClose":1750,"fiftyTwoWeekHigh":1889,"fiftyTwoWeekLow":952.5,"fiftyTwoWeekRange":"952.5 - 1889.0","fiftyDayAverage":1581.96,"twoHundredDayAverage":1393.29,"beta":0.63,"enterpriseValue":19323894311.110416,"forwardPE":17.2,"priceToBook":1.12,"priceToSales":0.76,"enterpriseToRevenue":0.99,"enterpriseToEbitda":7.15,"pegRatio":0,"ebitda":2702878226.711246,"ebitdaMargin":13.9,"freeCashflow":108953505.40496364,"operatingCashflow":1916184599.7568002,"totalDebt":6392809449.453886,"debtToEquity":46.7,"currentRatio":2.35,"returnOnAssets":3.5,"returnOnEquity":8,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":12,"targetMeanPrice":1805.83,"targetHighPrice":2180,"targetLowPrice":1400,"dividendRate":44,"payoutRatio":0.36,"fiveYearAvgDividendYield":3.34,"exDividendDate":1790640000,"insiderHeldPercent":3.2,"institutionHeldPercent":52.7,"sharesOutstanding":1356440705,"floatShares":1284603605,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":116.9,"epsForward":100.26,"revenuePerShare":2264.78,"bookValue":1539.66,"officers":[{"age":66,"name":"Mr. Koshiro  Kudo","title":"President, Presidential Executive Officer for Material Business Sector & Representative Director"},{"age":63,"name":"Mr. Toshiyasu  Horie","title":"CFO, Executive Officer of Strategy, Accounting, Finance & IR, Primary EO and Representative Director"},{"age":null,"name":"Mr. Futoshi  Hamamoto","title":"General Manager of Investor Relations"},{"age":null,"name":"Nobuhiro  Yamaguchi","title":"Lead Ex. Officer and Ex. Officer for General Affairs, Legal, Corporate Comm, Risk Mgt & Compliance"},{"age":null,"name":"Satoshi  Nishikawa","title":"Senior Executive Officer & Executive Officer for HR"},{"age":68,"name":"Mr. Shuichi  Sakamoto","title":"Primary Executive Officer for Health Care Business Sector (joint)"},{"age":67,"name":"Mr. Richard A. Packer","title":"Vice-Presidential Executive Officer & Executive Officer–Corporate Initiatives"},{"age":null,"name":"Hideyuki  Yamagishi","title":"Primary Executive Officer"}],"industry":"Conglomerates","irWebsite":"http://www.asahi-kasei.co.jp/asahi/en/ir/","website":"https://www.asahi-kasei.com","phone":"81 3 6699 3000"}}